Myrtelle Announces Presentation of Positive 6-month Post-Treatment Data in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the American Society of Gene and Cell Therapy 26th Annual Meeting
Wakefield, Mass., May, 16th, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
May 16, 2023
This article is featured on another website.
Go to article
July 16, 2025
Evox Therapeutics Expands Scientific Advisory Board
Additional world-leading expertise stands to further accelerate the Company’s pipeline programs targeting rare neurodegenerative diseases
July 16, 2025
Evox Therapeutics Expands Scientific Advisory Board
Additional world-leading expertise stands to further accelerate the Company’s pipeline programs targeting rare neurodegenerative diseases
July 8, 2025
Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.
July 8, 2025
Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.